Immune Bio 股份在扣除收入估计数后上升,而Inhibrx则下降,尽管预期值也下降。 INmune Bio shares rose after beating earnings estimates, while Inhibrx fell despite also beating expectations.

2026年1月13日, Inmune Bio 股份上升了2%, 在报告季度EPS为0.24美元之后, 击败率估计为0.07美元, 而Inhibrx生物科学公司则下降了6.5%, 尽管季度EPS为2.28美元, 也比预期高出0.66美元。 INmune Bio shares rose 2% on January 13, 2026, after reporting a quarterly EPS of ($0.24), beating estimates by $0.07, while Inhibrx Biosciences fell 6.5% despite a quarterly EPS of ($2.28), also beating expectations by $0.66. 专注于免疫学和神经退行性疾病的INmune的市值为3987万美元, 而用于组织修复的蛋白质疗法开发的Inhibrx的市值为106亿美元. INmune, focused on immunology and neurodegenerative diseases, has a market cap of $39.87 million, while Inhibrx, developing protein therapeutics for tissue repair, has a market cap of $1.06 billion. 分析师对两家公司的评分有好有坏, INMUNE持有“ Hold”共识, Inhibrx 则有“ruce”评分。 Analysts have mixed ratings for both companies, with INmune holding a "Hold" consensus and Inhibrx a "Reduce" rating.